Skip to main content

Table 1 Baseline demographic data, clinical manifestations, and the laboratory investigations of both groups

From: Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial

  Group I (itopride + norfloxacin) (number=40)
No. (%)
Group II (norfloxacin) (number=40)
No. (%)
Test of sig P value
Age (years) (mean± SD) 57.50 ± 6.48 59.40 ± 6.16 t=1.34 0.183
Gender     
 Male 21 (52.5) 25 (62.5) χ2= 0.81 0.366
 Female 19 (47.5) 15 (37.5)   
Abdominal pain 39 (97.5) 37 (92.5) FE=1.05 0.615
Fever 31 (77.5) 34 (85.0) χ2= 0.73 0.390
Hepatic encephalopathy 8 (20.0) 9 (22.5) χ2= 0.07 0.785
Hemoglobin (g/dl) 10.33 ± 1.34 9.83 ± 1.10 t=1.82 0.072
Platelets (cell× 103/mm3) 122.67 ± 73.03 146.62 ± 77.41 U=1.54 0.122
Total leucocytic count (cell× 103/mm3) 5.85 ± 3.42 6.51 ± 4.58 U=0.476 0.634
S. creatinine (mg/dl) 1.08 ± 0.58 1.16 ±0.40 U=1.61 0.106
S urea (mg/dl) 56.47 ± 41.81 52.19 ± 29.86 U=0.09 0.923
AST (u/l) 52.67 ± 36.43 50.70 ± 33.67 U=0.24 0.810
ALT (u/l) 41.82 ± 27.27 36.62 ±17.36 U=0.28 0.776
S. albumin (g/dl) 2.51 ± 0.50 2.61 ± 0.41 t=0.97 0.335
S. Bilirubin (mg/dl) 2.80 ± 2.68 3.82 ± 3.69 U=0.90 0.368
INR 1.56 ± 0.42 1.65 ± 0.45 t=0.86 0.389
CRP (mg/l) 38.86 ± 37.59 31.00 ±24.56 U=0.45 0.649